Cellectis (NASDAQ:CLLS) Announces Earnings Results

Cellectis (NASDAQ:CLLS) posted its quarterly earnings results on Friday, August 7th. The biotechnology company reported ($0.22) earnings per share for the quarter, beating analysts’ consensus estimates of ($0.26) by $0.04, Zacks reports. Cellectis had a negative return on equity of 94.19% and a negative net margin of 102.34%.The firm had revenue of $6.90 million during the quarter, compared to the consensus estimate of $11.05 million.

Cellectis Stock Performance

Cellectis stock traded down $0.05 during midday trading on Tuesday, reaching $3.30. 9,821 shares of the company’s stock were exchanged, compared to its average volume of 35,564. The stock’s 50-day simple moving average is $2.99 and its 200 day simple moving average is $3.39. The firm has a market cap of $331.12 million, a price-to-earnings ratio of -5.08 and a beta of 2.91. The company has a debt-to-equity ratio of 1.61, a quick ratio of 1.37 and a current ratio of 1.37. Cellectis has a 52 week low of $2.35 and a 52 week high of $5.48.

Analysts Set New Price Targets

Several equities research analysts have recently commented on CLLS shares. Weiss Ratings reissued a “sell (d-)” rating on shares of Cellectis in a report on Friday, July 17th. Barclays initiated coverage on shares of Cellectis in a report on Thursday, May 28th. They set an “overweight” rating and a $9.00 target price on the stock. One equities research analyst has rated the stock with a Strong Buy rating, four have given a Buy rating and one has assigned a Sell rating to the company. According to MarketBeat, the company currently has a consensus rating of “Moderate Buy” and an average price target of $7.00.

Institutional Trading of Cellectis

A number of hedge funds have recently made changes to their positions in the business. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC boosted its stake in shares of Cellectis by 228.4% during the 1st quarter. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC now owns 4,722,664 shares of the biotechnology company’s stock worth $5,856,000 after acquiring an additional 3,284,409 shares during the period. UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC bought a new stake in Cellectis in the 4th quarter valued at $15,385,000. Citadel Advisors LLC acquired a new stake in Cellectis during the 3rd quarter valued at $633,000. Marshall Wace LLP lifted its holdings in Cellectis by 1,610.3% during the 4th quarter. Marshall Wace LLP now owns 178,473 shares of the biotechnology company’s stock valued at $864,000 after purchasing an additional 168,038 shares during the last quarter. Finally, Millennium Management LLC boosted its position in Cellectis by 61.9% during the third quarter. Millennium Management LLC now owns 57,740 shares of the biotechnology company’s stock worth $165,000 after purchasing an additional 22,080 shares during the period. 63.90% of the stock is owned by institutional investors and hedge funds.

About Cellectis

Cellectis is a clinical‐stage biopharmaceutical company specializing in the development of gene‐edited cell therapies for oncology. Founded in 1999 and headquartered in Paris, France, the company also maintains operations in New York City and Raleigh, North Carolina. Cellectis applies its proprietary TALEN genome editing platform to engineer allogeneic chimeric antigen receptor T‐cell (CAR‐T) candidates designed to target blood cancers and solid tumors.

The company’s core business activities encompass the discovery, development and manufacturing of off‐the‐shelf immunotherapies.